CUSTOM RECOMBINANT PROTEIN PRODUCTION SERVICES MARKET ANALYSIS

Market Challenges And Opportunities

Global Custom Recombinant Protein Production Services Market– Drivers

• Increasing prevalence of diseases such as diabetes, cancer, heart disorders: Recombinant proteins include recombinant hormones, growth factors, interferons, interleukins, blood clotting factors, tumor necrosis factors, thrombolytic drugs, and enzymes for treating major diseases such as diabetes, dwarfism, congestive heart failure, myocardial infarction, cerebral apoplexy, neutropenia, multiple sclerosis, thrombocytopenia, hepatitis, anemia, Crohn’s disease, rheumatoid arthritis, asthma, and cancer, which is expected to drive market growth over the forecast period. Moreover, recombinant proteins are used for the development of vaccines, which can help treat and prevent autoimmune diseases such as rheumatoid arthritis and inflammatory bowel diseases (IBD), Thus, the increasing prevalence of such diseases is expected to drive market growth. For instance, according to the data provided by Breastcancer.org, is an education and support lifeline for millions of people affected by breast cancer in March 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive (in situ) breast cancer.
• Increasing research and development activities for the development of recombinant protein-based products by the key players in the market: Recombinant proteins help to understand the basic and fundamental principles of an organism. They are used to identify and locate the position of the protein encoded by a specific gene and to identify the function of other genes in various cellular activities such as cell signaling, growth, metabolism, replication and death, transcription, translation, and protein modification. For instance, in February 2022, CORBEVAX, an indigenously developed receptor binding domain (RBD) recombinant protein sub-unit vaccine for COVID-19, developed by Biological E Limited, a biotechnology and biopharmaceutical company, received approval for emergency use authorization from the Drug Controller General of India (DCGI) for the 12-18 age group. The Department of Biotechnology (DBT) and its Public Sector Undertaking (PSU), the Biotechnology Industry Research Assistance Council (BIRAC), had supported the company’s COVID-19 vaccine candidate from the pre-clinical stage through Phase III clinical studies.

Global Custom Recombinant Protein Production Services Market: Restraint

• Complex manufacturing process of recombinant proteins: Recombinant protein production and manufacturing is a complex process, which may act as a restraint on market growth. The recombinant protein manufacturing process is complex and requires higher protein expression, purification, and processing. Moreover, each product requires standardization for large-scale production and purification. As only large-scale production can fulfill the growing demand, thus, it should be cost-effective. Use of recombinant DNA technology for large-scale production of proteins requires a lot of time, labor, and resources. The over-expression and aggregation of the target protein might cause physiological changes in the host cells, thereby causing protein degradation and the production of proteins by the host proteases. Also, for therapeutic purposes, proper modifications and refolding of recombinant proteins are required after purification.  This requires development of new technologies for replacement of Complex manufacturing process of recombinant proteins